Jazz Pharmaceuticals 향후 성장

Future 기준 점검 4/6

Jazz Pharmaceuticals (는) 각각 연간 33.5% 및 7.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 33.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 21.1% 로 예상됩니다.

핵심 정보

33.5%

이익 성장률

33.65%

EPS 성장률

Pharmaceuticals 이익 성장	11.2%
매출 성장률	7.4%
향후 자기자본이익률	21.08%
애널리스트 커버리지	Good
마지막 업데이트	09 Apr 2026

최근 향후 성장 업데이트

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 09

Recent updates

Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook

Feb 26

Beyond the Patent Cliff: Unlocking the Cash Machine

Feb 21Jazz Pharmaceuticals (JAZZ), headquartered in Dublin, Ireland, enters 2026 as a highly efficient cash generator that the broader market seems to continually misunderstand. Following a massive 41% earnings beat late last year, the company is proving that it is successfully navigating the transition away from its legacy reliance on the sleep disorder drug Xyrem.

Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified

Nov 18

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 09

Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E

Jul 21

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

Jul 03

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

May 09

이익 및 매출 성장 예측

NasdaqGS:JAZZ - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	5,223	1,231	1,831	1,788	12
12/31/2027	4,797	916	1,646	1,245	15
12/31/2026	4,449	780	1,555	1,253	15
12/31/2025	4,268	-356	1,146	1,356	N/A
9/30/2025	4,158	-368	1,239	1,392	N/A
6/30/2025	4,087	-405	1,240	1,316	N/A
3/31/2025	4,065	482	1,488	1,558	N/A
12/31/2024	4,069	560	1,348	1,396	N/A
9/30/2024	3,993	463	1,102	1,165	N/A
6/30/2024	3,910	395	1,017	1,073	N/A
3/31/2024	3,843	331	983	1,039	N/A
12/31/2023	3,834	415	1,049	1,092	N/A
9/30/2023	3,794	80	867	1,267	N/A
6/30/2023	3,763	-87	987	1,377	N/A
3/31/2023	3,738	-156	918	1,384	N/A
12/31/2022	3,659	-224	774	1,272	N/A
9/30/2022	3,584	-19	984	1,108	N/A
6/30/2022	3,481	-52	809	964	N/A
3/31/2022	3,300	-450	622	702	N/A
12/31/2021	3,094	-330	733	779	N/A
9/30/2021	2,863	-161	711	787	N/A
6/30/2021	2,626	40	708	771	N/A
3/31/2021	2,436	518	750	912	N/A
12/31/2020	2,364	239	520	900	N/A
9/30/2020	2,280	179	455	801	N/A
6/30/2020	2,217	133	478	881	N/A
3/31/2020	2,188	280	509	847	N/A
12/31/2019	2,162	523	594	776	N/A
9/30/2019	2,056	609	N/A	907	N/A
6/30/2019	1,988	656	N/A	791	N/A
3/31/2019	1,954	486	N/A	834	N/A
12/31/2018	1,891	447	N/A	799	N/A
9/30/2018	1,851	520	N/A	785	N/A
6/30/2018	1,793	434	N/A	753	N/A
3/31/2018	1,687	447	N/A	696	N/A
12/31/2017	1,619	488	N/A	693	N/A
9/30/2017	1,579	372	N/A	669	N/A
6/30/2017	1,541	399	N/A	613	N/A
3/31/2017	1,528	408	N/A	605	N/A
12/31/2016	1,488	397	N/A	592	N/A
9/30/2016	1,432	363	N/A	531	N/A
6/30/2016	1,399	361	N/A	573	N/A
3/31/2016	1,352	335	N/A	587	N/A
12/31/2015	1,325	330	N/A	532	N/A
9/30/2015	1,312	328	N/A	545	N/A
6/30/2015	1,278	266	N/A	499	N/A

애널리스트 향후 성장 전망

수입 대 저축률: JAZZ 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: JAZZ (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: JAZZ 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: JAZZ 의 수익(연간 7.4%)이 US 시장(연간 10.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: JAZZ 의 수익(연간 7.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: JAZZ의 자본 수익률은 3년 후 21.1%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/09 11:35
종가	2026/04/09 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Jazz Pharmaceuticals plc는 46명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Joel Beatty	Baird
Brian Skorney	Baird
null null	Baird

Jazz Pharmaceuticals 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Jazz Pharmaceuticals plc Provides Earnings Guidance for Full Year 2026

Price target increased by 8.8% to US$205

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2025

Consensus EPS estimates have been downgraded.

Recent updates

Jazz Pharmaceuticals Plc Presents Research On Epidiolex And Xywav At The American Academy Of Neurology Annual Meeting

Co-Founder & Chairman notifies of intention to sell stock

Insider notifies of intention to sell stock

Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook

Full year 2025 earnings: EPS exceeds analyst expectations

Jazz Pharmaceuticals plc Provides Earnings Guidance for Full Year 2026

Beyond the Patent Cliff: Unlocking the Cash Machine

Jazz Pharmaceuticals plc to Report Q4, 2025 Results on Feb 24, 2026

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer, Effective January 1, 2026

Insider recently sold US$379k worth of stock

Senior VP & Chief Accounting Officer notifies of intention to sell stock

Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting

Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium

Co-Founder & Chairman exercised options and sold US$4.2m worth of stock

Co-Founder & Chairman recently sold US$3.1m worth of stock

Price target increased by 8.8% to US$205

Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified

Jazz Pharmaceuticals plc Announces Positive Top-Line Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera®?

Jazz Pharmaceuticals plc Showcases New Clinical and Translational Data for Modeyso (Dordaviprone) in H3 K27M-Mutant Diffuse Midline Glioma at SNO 2025

New major risk - Financial position

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2025

Jazz Pharmaceuticals plc Announces Board Changes, Effective December 1, 2025

Jazz Pharmaceuticals plc to Report Q3, 2025 Results on Nov 05, 2025

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

Co-Founder & Chairman notifies of intention to sell stock

FDA Approves Jazz Pharmaceuticals plc's Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc Showcases Phase 4 Data Demonstrating Xywav®? Oral Solution Treatment Effects and Real-World Evidence At World Sleep and Psych Congresses

Jazz Pharmaceuticals plc Announces Modeyso (Dordaviprone) Included in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for H3 K27m-Mutant Diffuse Glioma

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Jazz Pharmaceuticals plc Announces U.S. Fda Approval of Modeyso™? (Dordaviprone) as the First and Only Treatment for Recurrent H3 K27m-Mutant Diffuse Midline Glioma

Second quarter 2025 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2025

Co-Founder notifies of intention to sell stock

Jazz Pharmaceuticals plc to Report Q2, 2025 Results on Aug 05, 2025

Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E

Jazz Pharmaceuticals plc Announces President Changes, Effective August 11, 2025

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

Jazz Pharmaceuticals plc Receives European Commission Marketing Authorization for Ziihera (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc Announces U.S. FDA Accepts Supplemental New Drug Application for Zepzelca (Lurbinectedin) in Combination with Atezolizumab (Tecentriq) as First-Line Maintenance Treatment for People with Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

Jazz Pharmaceuticals plc to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav®? in Sleep Conditions and Associated Comorbidities at SLEEP 2025

Girard Sharp LLP and Motley Rice LLC Announce Proposed Settlements in re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 24, 2025

Independent Director recently bought US$10.0m worth of stock

Consensus EPS estimates have been downgraded.

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Jazz Pharmaceuticals plc Updates Unaudited Earnings Guidance for the Full Year of 2025

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist?

Jazz Pharmaceuticals plc Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc to Report Q1, 2025 Results on May 06, 2025

Jazz Pharmaceuticals plc Enters into a Preliminary Class Settlement Agreement with the Class of Indirect Xyrem Purchasers

Investor sentiment deteriorates as stock falls 18%

New major risk - Shareholder dilution

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.

Executive VP & Chief Legal Officer recently sold US$551k worth of stock

Senior VP & Chief Accounting Officer notifies of intention to sell stock

Full year 2024 earnings: EPS exceeds analyst expectations

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2025

Jazz Pharmaceuticals plc to Report Q4, 2024 Results on Feb 25, 2025

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025

Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits

Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?)

Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Executive VP & Chief Legal Officer recently sold US$457k worth of stock